Compare ESLA & ARAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESLA | ARAY |
|---|---|---|
| Founded | 2021 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.9M | 55.2M |
| IPO Year | N/A | 2006 |
| Metric | ESLA | ARAY |
|---|---|---|
| Price | $1.68 | $0.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.00 | $3.50 |
| AVG Volume (30 Days) | 163.3K | ★ 1.3M |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $0.33 |
| 52 Week High | $3.15 | $2.10 |
| Indicator | ESLA | ARAY |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 50.13 |
| Support Level | $1.48 | $0.34 |
| Resistance Level | $2.07 | $0.48 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 16.00 | 71.11 |
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.